In a column for christophermschroeder.substack.com, strategy consultant Ruby Wang argues that China has transformed into a global health superpower driven by rapid AI integration and massive health data access.
Patients ultimately care about efficacy, cost, and timely access rather than the country of origin for their medicines, according to Wang, founder and managing director of LINTRIS Health. Her new book, China Cure: The Rise of Biotech, AI Medicine and Global Health Superpower, examines the rapid shift in global life sciences.
Silicon Valley biotech entrepreneurs interviewed by Schroeder noted two primary competitive advantages held by China. The first advantage involves massive access to health data for applications involving fetal tissue and relaxed data privacy standards. The second advantage is the speed at which China moves drugs and medical devices through regulatory approvals, often taking a third of the time required in Western nations.
“You think in terms of speed to market, and of course that it’s important. But what many misunderstand is that if one goes through a regulatory process in a third of the time, that drug STARTS with a one billion dollar cost advantage,” an American pharmaceutical executive told Schroeder.
Global Medical Competition
Wang writes that healthcare competition operates differently across commercial and scientific domains. Companies fiercely compete for talent, intellectual property, investment, clinical trials, and market share, while governments seek to protect domestic industries and secure critical supply chains.
Science and medical knowledge build on discoveries made across generations and borders. A cancer treatment developed in Beijing can benefit a patient in Boston just as easily as a Western breakthrough helps a patient in China, Wang argues.
Patients don’t particularly care which country discovered their medicine. They care whether the treatment works, whether they can afford it and whether they can get it in time,” Wang told christophermschroeder.substack.com.
Influences on Chinese healthcare delivery
Cultural differences heavily influence healthcare delivery in China compared to Western nations like Britain and America. Patient autonomy and strict confidentiality remain fundamental ethical principles in the West, where doctors cannot share diagnoses with relatives without explicit adult consent.
Chinese healthcare traditionally incorporates a greater degree of family involvement, where relatives frequently participate in consultations and treatment decisions. Wang notes that Chinese law increasingly recognizes individual informed consent, yet the historical expectation of shared familial responsibility persists.
China’s rapid digital transformation over the past two decades has accustomed hundreds of millions of citizens to mobile platforms for everyday services. Healthcare has integrated into this digital culture, allowing patients to book appointments, consult doctors, pay for medications, and arrange app-based home deliveries.
Technological Innovation Strengths
China has developed deep expertise in manufacturing, process engineering, and optimizing existing technologies. In biotechnology, these capabilities translate into rapid drug development, particularly in advanced oncology treatments.
Chinese pharmaceutical firms excel at producing antibody-drug conjugates, which use targeted antibodies to deliver potent drugs directly to cancer cells. They also manufacture bispecific antibodies capable of targeting two distinct biological pathways simultaneously.
Akeso’s ivonescimab represented a major turning point for the industry when a Phase III clinical trial demonstrated superior progression-free survival compared to Merck’s Keytruda in specific lung cancer patient groups. International confidence in Chinese biotech assets surged over the past decade, with the announced value of out-licensing deals increasing more than fiftyfold.
Answering key questions about China Cure
What is the core argument of China Cure?
Wang argues that China has emerged as a global health superpower by combining massive health data access, rapid regulatory approval pathways, and sophisticated AI-driven biotech innovation.
How do Chinese regulatory timelines compare to the West?
Regulatory processes in China can move products through approvals in a third of the time or less compared to Western markets, providing a significant cost advantage for drug developers.
Which therapeutic areas show the strongest growth in China?
Oncology leads China’s biotech development model, particularly through sophisticated advancements in antibody-drug conjugates and bispecific antibodies for cancer treatment.
What role does digital technology play in Chinese healthcare?
Hundreds of millions of consumers utilize mobile apps for everyday services, which allows healthcare providers to deliver appointments, consultations, and medications efficiently.